Epidemiology of Candida species infections in critically ill non-immunosuppressed patients

被引:693
作者
Eggimann, P
Garbino, J
Pittet, D [1 ]
机构
[1] Univ Hosp Geneva, Dept Internal Med, Infect Control Programme, CH-1211 Geneva 14, Switzerland
[2] Univ Hosp Geneva, Med Clin 2, Geneva, Switzerland
[3] Univ Hosp Geneva, Med Intens Care Unit, Geneva, Switzerland
[4] Univ Hosp Geneva, Dept Internal Med, Div Infect Dis, Geneva, Switzerland
关键词
D O I
10.1016/S1473-3099(03)00801-6
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
A substantial proportion of patients become colonised with Candida spp during hospital stay, but only few subsequently develop severe infection. Clinical signs of severe infection manifest early but lack specificity until late in the course of the disease, thus representing a particular challenge for diagnosis. Mostly nosocomial, invasive candidiasis occurs in only 1-8% of patients admitted to hospitals, but in around 10% of patients housed in intensive care units where it can represent up to 15% of all nosocomial infections. We review the epidemiology of invasive candidiasis in non-immunocompromised, critically ill patients with special emphasis on disease trends over time, pathophysiology, diagnostic approach, risk factors, and impact. Recent epidemiological data suggesting that the emergence of non-albicans candida strains with reduced susceptibility to azoles, previously linked to the use of new antifungals for empiric and prophylactic therapy in immunocompromised patients, may not have occurred in the critically ill. Management of invasive candidiasis in these patients will be addressed in the December issue of The Lancet Infectious Diseases.
引用
收藏
页码:685 / 702
页数:18
相关论文
共 177 条
  • [1] The epidemiology of hematogenous candidiasis caused by different Candida species
    AbiSaid, D
    Anaissie, E
    Uzun, O
    Raad, I
    Pinzcowski, H
    Vartivarian, S
    [J]. CLINICAL INFECTIOUS DISEASES, 1997, 24 (06) : 1122 - 1128
  • [2] Candidemia in a tertiary care hospital:: Epidemiology and factors influencing mortality
    Alonso-Valle, H
    Acha, O
    García-Palomo, JD
    Fariñas-Alvarez, C
    Fernánez-Mazarrasa, C
    Fariñas, MC
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2003, 22 (04) : 254 - 257
  • [3] Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature
    Anaissie, EJ
    Darouiche, RO
    AbiSaid, D
    Uzun, O
    Mera, J
    Gentry, LO
    Williams, T
    Kontoyiannis, DP
    Karl, CL
    Bodey, GP
    [J]. CLINICAL INFECTIOUS DISEASES, 1996, 23 (05) : 964 - 972
  • [4] Predictors of adverse outcome in cancer patients with candidemia
    Anaissie, EJ
    Rex, JH
    Uzun, Ö
    Vartivarian, S
    [J]. AMERICAN JOURNAL OF MEDICINE, 1998, 104 (03) : 238 - 245
  • [5] ARMSTRONG D, 1995, BAILLIERE CLIN INF D, V2, P17
  • [6] Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus
    Ascioglu, S
    Rex, JH
    de Pauw, B
    Bennett, JE
    Bille, J
    Crokaert, F
    Denning, DW
    Donnelly, JP
    Edwards, JE
    Erjavec, Z
    Fiere, D
    Lortholary, O
    Maertens, J
    Meis, JF
    Patterson, TF
    Ritter, J
    Selleslag, D
    Shah, PM
    Stevens, DA
    Walsh, TJ
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) : 7 - 14
  • [7] BANERJEE SN, 1991, AM J MED S3B, V91, P86
  • [8] BECKSAGUE CM, 1993, J INFECT DIS, V167, P1247, DOI 10.1093/infdis/167.5.1247
  • [9] Candida albicans:: A molecular revolution built on lessons from budding yeast
    Berman, J
    Sudbery, PE
    [J]. NATURE REVIEWS GENETICS, 2002, 3 (12) : 918 - 930
  • [10] Effects of nosocomial candidemia on outcomes of critically ill patients
    Blot, SI
    Vandewoude, KH
    Hoste, EA
    Colardyn, FA
    [J]. AMERICAN JOURNAL OF MEDICINE, 2002, 113 (06) : 480 - 485